FindTrial
Sign In

Hyperpolarized Carbon C 13 Pyruvate

DRUG11 trials

Sponsors

Daniel M. Spielman, M.D. Anderson Cancer Center, Susan Chang, University of California, San Francisco, Zhen Wang, MD

Conditions

Benign Kidney NeoplasmGliomaKidney NeoplasmMalignant Central Nervous System NeoplasmMeningiomaMetastatic Malignant Neoplasm in the Central Nervous SystemPSA Level Greater Than TenPancreatic Ductal Adenocarcinoma

Phase 1

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Detecting Lactate and Bicarbonate in Participants With Central Nervous System Tumors
CompletedNCT03565367
Daniel M. SpielmanMalignant Central Nervous System Neoplasm, Metastatic Malignant Neoplasm in the Central Nervous System
Start: 2018-11-06End: 2019-06-20Updated: 2023-12-21
Hyperpolarized Imaging in Diagnosing Participants With Glioma
RecruitingNCT03739411
Susan ChangGlioma
Start: 2015-12-09End: 2028-06-01Target: 140Updated: 2026-03-27
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
RecruitingNCT03830151
M.D. Anderson Cancer CenterPrimary Brain Neoplasm
Start: 2019-05-16End: 2028-12-31Target: 13Updated: 2026-01-13
Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma
RecruitingNCT04540107
Susan ChangRecurrent WHO Grade III Glioma, Recurrent World Health Organization (WHO) Grade II Glioma, WHO Grade II Glioma +1
Start: 2017-01-11End: 2027-01-31Target: 300Updated: 2025-01-10
An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy
RecruitingNCT04589624
M.D. Anderson Cancer CenterThyroid Gland Carcinoma
Start: 2020-08-12End: 2027-05-31Target: 42Updated: 2025-11-21
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
RecruitingNCT06014905
Javier Villaneuva-Meyer, MDMeningioma
Start: 2023-09-01End: 2026-09-30Target: 50Updated: 2025-05-25

Phase 2

Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
WithdrawnNCT03581500
M.D. Anderson Cancer CenterProstate Adenocarcinoma, PSA Level Greater Than Ten, Stage IIB Prostate Cancer AJCC v8 +7
Start: 2019-02-06End: 2024-10-16Updated: 2025-04-23
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance
RecruitingNCT03933670
University of California, San FranciscoProstate Adenocarcinoma, Prostate Cancer
Start: 2018-07-18End: 2028-06-30Target: 60Updated: 2026-02-18
Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors
Active, not recruitingNCT04258462
Zhen Wang, MDBenign Kidney Neoplasm, Kidney Neoplasm, Renal Cell Cancer
Start: 2019-01-15End: 2026-10-31Updated: 2026-02-23
Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma
TerminatedNCT04565327
Zhen Wang, MDPancreatic Ductal Adenocarcinoma
Start: 2020-08-14End: 2022-11-01Updated: 2023-11-13

Unknown Phase

Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
Active, not recruitingNCT04286386
M.D. Anderson Cancer CenterProstate Adenocarcinoma
Start: 2019-12-19End: 2026-04-30Target: 130Updated: 2025-10-27